A recent survey reveals a startling trend: One in eight adults in the United States are now using Ozempic, Wegovy, or similar GLP-1 drugs, according to the KFF Health Tracking Poll. This widespread adoption has raised concerns about affordability and public skepticism regarding the Trump administration's efforts to lower prescription costs. The poll highlights several key findings that shed light on the complex landscape of GLP-1 drug usage and its implications.
Prevalence and Demographics: The survey indicates that approximately 12% of U.S. adults use GLP-1 drugs, with a higher prevalence among adults aged 50-64 (22%) and women (15% vs. 9% of men). This data underscores the growing popularity of these medications across specific age groups and genders.
Affordability Crisis: Despite the drugs' effectiveness, affordability remains a significant barrier. Over half (56%) of GLP-1 users struggle with the cost, even with health insurance. Shockingly, 27% of insured users still end up paying the full cost themselves, revealing gaps in insurance coverage for these treatments.
Reasons for Discontinuation: The poll uncovers the primary reasons why patients stop taking GLP-1 drugs. High costs (14%) and side effects (13%) are the leading factors, far surpassing the fraction (5%) who discontinue due to improved health conditions. This highlights the urgent need for more affordable alternatives.
Public Skepticism: Public trust in the Trump administration's efforts to lower drug prices is waning. Only 38% of adults believe the administration's plans will successfully reduce prescription drug costs. This skepticism persists despite recent announcements aimed at lowering drug prices for state Medicaid programs and IVF treatments.
Access and Sources: While most users obtain GLP-1 drugs through traditional medical channels, a notable minority turns to alternative providers. The poll reveals that 76% of users receive the medication from their doctors, but 17% acquire it from online providers or websites, and 9% from medical spas or aesthetic centers. This diversification in access methods warrants further investigation and regulation.
